Urea Cycle Disorders, Inborn Clinical Trial
Official title:
Protein Sorbent Properties of Montmorillonite in Vitro and in Vivo Models
Montmorillonite (MONT) is a phyllosilicate layered mineral with unique physicochemical
properties, such as swelling and cation exchange capability.
The aim of this project is to study, in healthy volunteers, the in vivo ability of MONT to
reduce protein intestinal uptake. Furthermore, the study analyzed in vitro the MONT ability
of immobilizing proteins.
Montmorillonite (MONT) is a phyllosilicate layered mineral; chemically it is hydrated sodium
calcium aluminium magnesium silicate hydroxide. Potassium, iron, and other cations are
common substitutes and the exact ratio of cations varies with source.
Due to its unique physicochemical properties, such as swelling and cation exchange
capability, as well its mechanical and thermal stability, MONT can be efficiently used as
matrix for immobilization of proteins with high molecular weight (e.g. Albumin) and proteins
with low molecular weight (e.g.Aflatoxines). Therefore, MONT is used for therapeutic
purposes, in pharmaceutical formulations and in food preparations. In vitro assays made in
our laboratory, showed that MONT absorbs, in stable manner, alimentary proteins:
beta-lactoglobulins, alfa lactoalbumines and the ratio MONT-protein (w/w) 1:3, 1:5, 1:15,
results in the protein capture of 50, 27, 0 % of proteins respectively.
The aim of this project is to study, in healthy volunteers, the in vivo ability of MONT to
reduce protein intestinal uptake evaluated with the blood MONT- protein ratio. Furthermore,
the study analyzed in vitro the MONT ability of immobilizing proteins at different ratio
(w/w) 1:3, 1:5, 1:15.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02111200 -
Comparative Efficacy of Phenylbutyrate (PBA) vs. Benzoate in Urea Cycle Disorders
|
N/A | |
| Completed |
NCT03064048 -
Nitric Oxide Supplementation on Neurocognitive Functions in Patients With ASLD
|
N/A | |
| Withdrawn |
NCT01341379 -
Increasing Ureagenesis in Inborn Errors of Metabolism With N-Carbamylglutamate
|
Phase 2 | |
| Recruiting |
NCT06255782 -
An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency (OTC-HOPE)
|
Phase 1/Phase 2 |